Study of Paclitaxel Protein Bound + Gemcitabine + Cisplatin + Hydrochloroquine as Treatment in Untreated Pancreas Cancer
A Phase II Study of Paclitaxel Protein Bound + Gemcitabine + Cisplatin+ Hydroxychlororoquine as Preoperative Treatment in Patients With Untreated Resectable, Borderline Resectable and Locally Advanced Adenocarcinoma of the Pancreas
Sponsor: HonorHealth Research Institute
This PHASE2 trial investigates Borderline Resectable Pancreatic Adenocarcinoma and Locally Advanced Pancreatic Adenocarcinoma and is currently ongoing. HonorHealth Research Institute leads this study, which shows 10 recorded versions since 2020 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Active Not Recruiting PHASE2
-
Jun 2025 — Sep 2025 [monthly]
Active Not Recruiting PHASE2
-
Apr 2025 — Jun 2025 [monthly]
Active Not Recruiting PHASE2
-
Nov 2024 — Apr 2025 [monthly]
Active Not Recruiting PHASE2
-
Sep 2024 — Nov 2024 [monthly]
Active Not Recruiting PHASE2
▶ Show 5 earlier versions
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2
-
Sep 2023 — Jul 2024 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
May 2023 — Sep 2023 [monthly]
Recruiting PHASE2
-
Jun 2022 — May 2023 [monthly]
Recruiting PHASE2
-
Jan 2021 — Jun 2022 [monthly]
Recruiting PHASE2
First recorded
Dec 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- HonorHealth Research Institute
For direct contact, visit the study record on ClinicalTrials.gov .